Sumitomo Pharma

Sumitomo Pharma has faced significant financial challenges, with annual revenue plummeting 43% to ¥314.5 billion ($1.9 billion) during its last fiscal year. The company's current TTM revenue stands at $2.14 billion, showing a continued decline from $2.33 billion in 2023 and $4.40 billion in 2022. Under new CEO leadership, the company is implementing restructuring measures including workforce reductions, having already cut approximately 1,260 U.S. jobs since early 2023, with potential early retirement options being considered for its Japanese operations as the company adjusts to changes in business scale.